Key facts
- EpilepsyGTX’s last known valuation is $47.2M (Dec 2025).
- It has raised $47.5M; the latest was Early Stage VC ($32.5M) in Dec 2025.
- Notable investors include British Business Bank, UK Research and Innovation, AlbionVC, Zcube, Health Technology Holding — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for EpilepsyGTX
- ·The full record, as it builds
Funding rounds
No funding rounds for EpilepsyGTX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EpilepsyGTX
Developer of gene therapies designed for neurological disorder treatment. The company's platform utilizes genetic engineering techniques to modify cells, delivering therapeutic genes to targeted areas within the brain, often involving viral vectors and specialized delivery systems, enabling researchers and clinicians to explore potential treatments for epilepsy.
- Sector
- Healthcare
- HQ
- Canterbury, United Kingdom
- Founded
- 2021
- Employees
- 2
- Website
- epilepsygtx.com/
- Ownership
- Privately Held (backing)
EpilepsyGTX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EpilepsyGTX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EpilepsyGTX in its N-PORT filings yet. We sweep new filings monthly.